Indian J Pharmacol. 2012 Mar;44(2):238-42. doi: 10.4103/0253-7613.93857.

A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin.

Indian journal of pharmacology

Biswas Gopa, Jagatkumar Bhatt, Kovur G Hemavathi

PMID: 22529483 PMCID: PMC3326920 DOI: 10.4103/0253-7613.93857

Abstract

OBJECTIVES: To evaluate the efficacy of Amla in patients with type II hyperlipidemia and compare its hypolipidemic effects with those of simvastatin.

MATERIALS AND METHODS: Sixty type II hyperlipidemic patients of both sexes with plasma total cholesterol and low density lipoprotein level more than 240 mg% and 130 mg%, respectively, were selected for the trial. Out of total 60 selected patients, 40 were treated with Amla capsule (500 mg) daily for 42 days and 20 patients were given simvastatin capsule (20 mg) daily for 42 days. After the day of enrolment, all patients were followed up twice during the 42-day period. Blood samples were analyzed for various biochemical parameters and the values of Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Very Low Density Lipoprotein (VLDL) were measured before and after completion of the treatment with Amla and simvastatin. Cardiovascular parameters were recorded before and after completion of treatment.

RESULTS: Treatment with Amla produced significant reduction of TC (P<0.0001), LDL (P<0.0001), triglyceride (TG) and VLDL (P<0.0002), and a significant increase in HDL levels (P<0.0002). Similarly, treatment with simvastatin produced significant reduction of TC (P<0.0001), LDL (P<0.0009), TG and VLDL (P<0.017), and a significant increase in HDL levels (P<0.0001). Both treatments produced significant reduction in blood pressure; however, this beneficial effect was more marked in patients receiving Amla.

CONCLUSION: In view of the above findings, it is suggested that Amla produced significant hypolipidemic effect along with a reduction in blood pressure. Addition of Amla to the currently available hypolipidemic therapy would offer significant protection against atherosclerosis and coronary artery disease, with reduction in the dose and adverse effects of the hypolipidemic agents.

Keywords: Amla; clinical study; hyperlipidemia; lipid profile; simvastatin

References

1. Phytother Res. 2000 Dec;14(8):592-5 - PubMed
2. Lancet. 1999 May 22;353(9166):1763-4 - PubMed
3. JAMA. 1986 Nov 28;256(20):2823-8 - PubMed
4. Angiology. 1975 Oct;26(9):671-82 - PubMed
5. Am J Med. 2000 Aug 15;109(3):261-2 - PubMed
6. Indian J Exp Biol. 1995 Apr;33(4):261-8 - PubMed
7. Metabolism. 1981 Jun;30(6):605-9 - PubMed
8. Phytother Res. 1999 Sep;13(6):513-6 - PubMed
9. JAMA. 1984 Jan 20;251(3):365-74 - PubMed
10. J Ethnopharmacol. 2002 Jan;79(1):81-7 - PubMed
11. Circulation. 1990 Dec;82(6):1925-31 - PubMed
12. Arch Intern Med. 1999 Sep 13;159(16):1893-900 - PubMed
13. Am J Cardiol. 1992 Sep 15;70(7):733-7 - PubMed
14. N Engl J Med. 1999 Aug 5;341(6):410-8 - PubMed
15. Am J Cardiol. 1999 Apr 1;83(7):1146 - PubMed
16. Clin Chem. 1973 May;19(5):476-82 - PubMed
17. Lancet. 1975 Jan 4;1(7897):16-9 - PubMed
18. Eur J Clin Nutr. 1988 Nov;42(11):939-44 - PubMed
19. Lancet. 1994 Nov 19;344(8934):1383-9 - PubMed
20. J Ethnopharmacol. 1996 Feb;50(2):61-8 - PubMed
21. Indian J Exp Biol. 1999 Jul;37(7):676-80 - PubMed
22. Am J Cardiol. 1998 Nov 5;82(9A):13Q-21Q - PubMed
23. Ann Intern Med. 1989 Aug 1;111(3):253-5 - PubMed
24. Clin Chem. 1974 Apr;20(4):470-5 - PubMed
25. J Ethnopharmacol. 1999 Feb;64(2):135-9 - PubMed
26. Cardiovasc Toxicol. 2011 Sep;11(3):272-9 - PubMed
27. JAMA. 1998 May 27;279(20):1615-22 - PubMed

Publication Types

• Journal Article